Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Onyx BiotecNSE:ONYX +4.91%13 PS Ratio is 1.03 as of Jul. 17, 2026, which is 7% below its 10-year median of 1.11. GuruFocus rates NSE:ONYX with a GF Score™ of 13/100. The stock has 6 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Onyx Biotec ranks better than 80.75% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Onyx Biotec's share price is ₹39.55.
Onyx Biotec's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹38.53. Hence, Onyx Biotec's PS Ratio for today is 1.03.
The historical rank and industry rank for Onyx Biotec's PS Ratio or its related term are showing as below:
NSE:ONYX'
s PS Ratio Range Over the Past 10 Years
Min: 0.73 Med: 1.11 Max: 3.04
Current: 1.02
During the past 5 years, Onyx Biotec's highest PS Ratio was 3.04. The lowest was 0.73. And the median was 1.11.
NSE:ONYX's PS Ratio is ranked better than 80.75% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.86
vs NSE:ONYX: 1.02
Onyx Biotec Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Onyx Biotec was -6.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 21.30% per year.
During the past 5 years, Onyx Biotec's highest 3-Year average Revenue per Share Growth Rate was 21.30% per year. The lowest was 18.70% per year. And the median was 20.00% per year.
Back to Basics: PS Ratio
Onyx Biotec (NSE:ONYX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Onyx Biotec PS Ratio Related Terms
Onyx Biotec PS Ratio Historical Data
* Premium members only.
The historical data trend for Onyx Biotec's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Onyx Biotec's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Onyx Biotec PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Onyx Biotec's PS Ratio distribution charts can be found below:
* The bar in red indicates where Onyx Biotec's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Onyx Biotec's Share Price of today is ₹39.55.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Onyx Biotec's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹38.53.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Onyx Biotec (NSE:ONYX) has a PS Ratio of 1.03 as of Jul. 17, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Onyx Biotec and its competitors. This is near median its historical median of 1.11. Over the past decade, Onyx Biotec's PS Ratio has ranged from 0.73 to 3.04. According to the industry distribution chart, Onyx Biotec ranks #155 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 19.3%.
Is Onyx Biotec's PS Ratio too high?
Onyx Biotec's current PS Ratio of 1.03 is near median its 10-year median of 1.11. Over the past 10 years, this metric has ranged from a low of 0.73 to a high of 3.04. The Medical Devices & Instruments industry median PS Ratio is 2.86. Onyx Biotec's value of 1.03 is 64% below this industry median. Based on the distribution chart, Onyx Biotec ranks #155 out of 805 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Onyx Biotec has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Onyx Biotec's PS Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Onyx Biotec ranks #155 out of 805 companies for PS Ratio. This places Onyx Biotec in the top 19% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.86. Onyx Biotec's value of 1.03 is 64% below this benchmark. Historically, Onyx Biotec's own PS Ratio has ranged from 0.73 to 3.04 over the past decade. While the company's 10-year median is 1.11 vs. the industry median of 2.86, Onyx Biotec has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.86, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Onyx Biotec's current PS Ratio of 1.03 is 64% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Onyx Biotec and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Onyx Biotec's current PS Ratio is 1.03, which is near median its own 10-year median of 1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onyx Biotec stock overvalued right now?
Onyx Biotec (NSE:ONYX) has a current PS Ratio of 1.03. The current PS Ratio is 1.03, which is near median its 10-year median of 1.11 and 64% below the Medical Devices & Instruments industry median of 2.86. Onyx Biotec's overall GF Score™ is 13/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Onyx Biotec (NSE:ONYX), the current PS Ratio is 1.03 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Onyx Biotec Ltd is engaged in healthcare segment and offering Sterile Pharmaceutical products ,and acts as a pharmaceutical contract manufacturer. It offering products such as Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas. Key revenue is generated from Sterile Water for Injections .
13GF Score
Get the complete analysis for NSE:ONYX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ONYX has been successfully added to your 
